Stem Cell & Regenerative Medicine

Gene Editing, CRISPR Therapies & Regenerative Genomics

The integration of gene editing technologies, particularly CRISPR-Cas systems, into regenerative medicine has opened new frontiers for treating genetic and degenerative diseases. CRISPR-mediated genome engineering allows precise correction of pathogenic mutations, enabling the creation of patient-specific regenerative therapies. This session highlights innovations in gene-edited stem cells, organoids, and tissue models for translational applications. Researchers are exploring targeted approaches to enhance tissue repair, improve cellular function, and restore organ systems. Regenerative genomics combines high-throughput sequencing, bioinformatics, and functional genomics to identify key genes and pathways driving tissue regeneration. Ethical considerations, off-target effects, and delivery mechanisms remain critical challenges, with ongoing research focused on improving specificity, efficiency, and safety. Clinical trials utilizing CRISPR-edited hematopoietic stem cells, cardiomyocytes, and neuronal cells demonstrate the therapeutic potential of gene editing for conditions such as muscular dystrophy, inherited cardiac disorders, and neurodegenerative diseases. The session also emphasizes the role of epigenome editing, transcriptional regulation, and synthetic gene circuits to enhance regenerative outcomes. Attendees will explore how CRISPR and regenerative genomics are transforming personalized medicine, offering scalable, targeted, and next-generation therapeutic solutions for complex human disorders.